Although various inhibitors of PKM2 has been discovered, however, the researches on the discovery of bioactive entities targeting PKM2 are on-going, and the identification of selective, potent, and safer inhibitors could potentially contribute towards the development of effective and safer therapies for cancer patients. This evidence concerns the gene PKM and cancer.